NBTXR3 plus radiation for inoperable lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called NBTXR3, which makes cancer cells more sensitive to radiation. You'll get one injection of NBTXR3 into your lung tumor, followed by standard radiation. It is for people with early-stage non-small cell lung cancer who cannot have surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have non-small cell lung cancer (Stage I, II, or III) that cannot be removed with surgery (or you choose not to have surgery).
- You are well enough to carry out daily activities (ECOG score of 0-2).
- You have not had radiation to the lung or chest before (radiation for other areas like breast is okay).
- You can have a small injection of the study drug (NBTXR3) into the tumor, either through a bronchoscope or a CT-guided needle.
- You have not had more than one type of systemic therapy (chemotherapy, immunotherapy, etc.) and none within the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial tests a new schedule of chemo-radiation (fewer, stronger sessions) followed by an immunotherapy drug called tislelizumab. The goal is to see if this approach works better than the standard longer schedule for people with stage III lung cancer that can't be surgically removed.
This study tests whether adding NBTXR3 (given into a tumor) and targeted radiation to anti–PD-1/PD-L1 immunotherapy can improve cancer control in advanced cancers that have spread to the lung and/or liver. Participants may be assigned to different radiation approaches to try to trigger tumor shrinkage in both treated and nearby or distant tumor areas.
This trial tests a combination of radiation therapy, chemotherapy, and two newer cancer-fighting drugs (tislelizumab and surufatinib) for patients with Stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment.
This trial tests whether a special type of focused radiation therapy can effectively treat advanced non-small cell lung cancer (the most common type) as an upfront treatment. It may help patients avoid or delay chemotherapy while controlling their cancer.
This trial tests whether adding a NAD+ booster (NMN) to radiation and immunotherapy can help people with advanced lung cancer. It may improve the effectiveness of the treatment and help you live longer.
Hear when a new Locally Advanced Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.